The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Immune strategies in consolidation and maintenance for multiple myeloma
Joseph Mikhael, MD, MeD, FRCPC, FACP, Translational Genomics Research Institute (TGen), Phoenix, AZ & International Myeloma Foundation, Studio City, CA, provides insight into a session focusing on novel immune strategies, such as CAR-T and bispecific antibodies, in consolidation and maintenance for patients with multiple myeloma (MM). Dr Mikhael emphasizes the importance of determining optimal treatment duration and incorporating new mechanisms of action to achieve deeper, durable responses with better patient quality of life (QoL) and the potential for treatment discontinuation. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
